Seres Therapeutics (NASDAQ:MCRB) Stock Rating Upgraded by HC Wainwright

Seres Therapeutics (NASDAQ:MCRB) was upgraded by HC Wainwright to a “strong-buy” rating in a research note issued to investors on Tuesday,Zacks.com reports. HC Wainwright also issued estimates for Seres Therapeutics’ Q2 2026 earnings at ($2.07) EPS, Q3 2026 earnings at ($0.90) EPS, Q4 2026 earnings at ($0.93) EPS, FY2026 earnings at ($5.84) EPS, FY2027 earnings at ($2.87) EPS and FY2028 earnings at ($3.03) EPS.

Other equities analysts have also issued research reports about the stock. Canaccord Genuity Group restated a “buy” rating and issued a $22.00 target price on shares of Seres Therapeutics in a report on Friday, March 13th. Weiss Ratings downgraded Seres Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday, May 18th. Finally, Wall Street Zen raised Seres Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 6th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Seres Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $17.00.

Seres Therapeutics Stock Performance

Seres Therapeutics stock opened at $7.05 on Tuesday. The firm has a market cap of $68.24 million, a price-to-earnings ratio of -1.36 and a beta of 0.13. Seres Therapeutics has a 52-week low of $5.31 and a 52-week high of $29.98. The firm has a 50 day moving average price of $7.46 and a two-hundred day moving average price of $10.67.

Seres Therapeutics (NASDAQ:MCRB) last posted its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($2.08) EPS for the quarter, missing analysts’ consensus estimates of ($1.88) by ($0.20). The firm had revenue of $0.36 million for the quarter, compared to the consensus estimate of $0.36 million.

Institutional Investors Weigh In On Seres Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of MCRB. Invesco Ltd. raised its position in shares of Seres Therapeutics by 193.2% during the first quarter. Invesco Ltd. now owns 136,572 shares of the biotechnology company’s stock worth $96,000 after purchasing an additional 89,995 shares during the period. Goldman Sachs Group Inc. grew its position in Seres Therapeutics by 40.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 74,629 shares of the biotechnology company’s stock valued at $52,000 after purchasing an additional 21,679 shares during the period. Marshall Wace LLP bought a new stake in Seres Therapeutics during the 2nd quarter valued at $1,016,000. Vanguard Group Inc. increased its stake in Seres Therapeutics by 6.8% during the 3rd quarter. Vanguard Group Inc. now owns 311,889 shares of the biotechnology company’s stock valued at $6,001,000 after purchasing an additional 19,793 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC acquired a new position in Seres Therapeutics during the third quarter worth $557,000. Institutional investors own 59.34% of the company’s stock.

About Seres Therapeutics

Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.